Robert Yarchoan Selected Research

Highly Active Antiretroviral Therapy (HAART)

12/2007	Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma.
1/2007	Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity.
7/2006	Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapy.
8/2005	Therapy insight: AIDS-related malignancies--the influence of antiviral therapy on pathogenesis and management.
6/2003	Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
5/2002	Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert Yarchoan Research Topics

Disease

42	Kaposi Sarcoma (Kaposi's Sarcoma) 04/2024 - 03/2002
36	Neoplasms (Cancer) 09/2023 - 01/2003
17	Infections 01/2021 - 03/2002
16	Primary Effusion Lymphoma 01/2024 - 03/2007
14	Acquired Immunodeficiency Syndrome (AIDS) 01/2023 - 06/2003
11	Castleman Disease (Castleman's Disease) 01/2022 - 03/2007
8	Multi-centric Castleman's Disease 07/2023 - 12/2014
8	Lymphoma (Lymphomas) 01/2023 - 06/2003
7	Hypoxia (Hypoxemia) 01/2017 - 06/2003
4	HIV Infections (HIV Infection) 03/2022 - 11/2006
4	Neutropenia 01/2019 - 06/2006
4	Virus Diseases (Viral Diseases) 12/2018 - 07/2011
3	Thrombocytopenia (Thrombopenia) 01/2023 - 01/2017
3	COVID-19 01/2021 - 01/2020
3	Hypoalbuminemia 01/2019 - 08/2010
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2019 - 04/2010
3	Hypertension (High Blood Pressure) 01/2019 - 07/2010
3	Hyponatremia 12/2013 - 08/2010
2	Carcinogenesis 09/2023 - 04/2015
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2023 - 01/2021
2	T-Cell Leukemia (Leukemia, T Cell) 10/2022 - 01/2022
2	Viremia 01/2022 - 12/2016
2	Immune Reconstitution Inflammatory Syndrome 10/2018 - 04/2015
2	Prostatic Neoplasms (Prostate Cancer) 04/2012 - 07/2010
2	Fever (Fevers) 01/2012 - 08/2010
2	Cytopenia 01/2012 - 08/2010
2	Opportunistic Infections (Opportunistic Infection) 04/2010 - 07/2006
2	AIDS-related Kaposi sarcoma 12/2007 - 06/2006
2	AIDS-Related Lymphoma (Lymphoma, AIDS Related) 07/2006 - 08/2005
1	Respiratory Insufficiency (Respiratory Failure) 11/2022
1	Hypotension (Low Blood Pressure) 11/2022
1	Critical Illness (Critically Ill) 11/2022
1	Lymphopenia (Lymphocytopenia) 10/2022
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Burkitt Lymphoma (Burkitt's Lymphoma) 01/2022
1	Drug-Related Side Effects and Adverse Reactions 10/2020
1	Oral Manifestations 01/2020
1	Pneumonia (Pneumonitis) 09/2019

Drug/Important Bio-Agent (IBA)

18	CytokinesIBA 04/2024 - 01/2012
10	pomalidomideIBA 01/2023 - 04/2014
7	MicroRNAs (MicroRNA)IBA 11/2018 - 03/2007
6	Interleukin-6 (Interleukin 6)IBA 01/2024 - 08/2010
5	Rituximab (Mabthera)FDA Link 11/2020 - 04/2010
5	liposomal doxorubicin (Doxil)FDA Link 01/2019 - 01/2007
4	Antiviral Agents (Antivirals)IBA 01/2021 - 08/2005
4	AntigensIBA 08/2017 - 06/2010
4	Sorafenib (BAY 43-9006)FDA Link 01/2017 - 07/2010
3	Biomarkers (Surrogate Marker)IBA 04/2024 - 08/2010
3	Peptide Hydrolases (Proteases)FDA Link 10/2022 - 01/2020
3	pembrolizumabIBA 01/2022 - 09/2019
3	Bevacizumab (Avastin)FDA Link 01/2019 - 07/2010
3	Proteins (Proteins, Gene)FDA Link 01/2017 - 01/2012
3	Zidovudine (Retrovir)FDA LinkGeneric 09/2012 - 07/2007
3	Interleukin-12 (IL 12)IBA 12/2007 - 06/2006
2	Immune Checkpoint InhibitorsIBA 01/2022 - 10/2020
2	remdesivirIBA 01/2021 - 01/2020
2	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2021 - 08/2017
2	Circular RNAIBA 01/2021 - 12/2018
2	LigandsIBA 10/2020 - 09/2019
2	Monoclonal AntibodiesIBA 10/2020 - 09/2012
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 12/2003
2	RNA (Ribonucleic Acid)IBA 01/2020 - 01/2017
2	Transaminases (Aminotransferases)IBA 09/2019 - 06/2006
2	Interleukin-10 (Interleukin 10)IBA 01/2019 - 12/2013
2	InterleukinsIBA 01/2019 - 08/2010
2	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2018 - 03/2002
2	Lenalidomide (CC 5013)FDA Link 08/2017 - 04/2014
2	endothelial PAS domain-containing protein 1IBA 01/2017 - 06/2003
2	Messenger RNA (mRNA)IBA 01/2017 - 01/2015
2	C-Reactive ProteinIBA 12/2013 - 01/2012
2	Valganciclovir FDA Link 09/2012 - 06/2011
2	BilirubinIBA 04/2012 - 06/2006
2	AntibodiesIBA 08/2010 - 06/2010
2	Peptides (Polypeptides)IBA 08/2010 - 03/2010
1	11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA 01/2024
1	CarcinogensIBA 09/2023
1	daratumumabIBA 01/2023
1	Methionine (L-Methionine)FDA Link 10/2022
1	Cysteine (L-Cysteine)FDA Link 10/2022
1	CyclinsIBA 01/2022
1	palbociclibIBA 01/2022
1	InterferonsIBA 01/2022
1	ribociclibIBA 01/2022
1	abemaciclibIBA 01/2022
1	Interleukin-13IBA 01/2021
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2021
1	Methotrexate (Mexate)FDA LinkGeneric 11/2020
1	tocilizumab (atlizumab)FDA Link 01/2020
1	indoleIBA 01/2020
1	EstersIBA 01/2020
1	NucleotidesIBA 01/2020

Therapy/Procedure

44	Therapeutics 01/2023 - 01/2003
6	Highly Active Antiretroviral Therapy (HAART) 12/2007 - 05/2002
5	Art Therapy 09/2023 - 12/2016
4	Immunotherapy 01/2022 - 08/2017
3	Lasers (Laser) 01/2006 - 01/2004
2	Drug Therapy (Chemotherapy) 01/2021 - 12/2007
1	Secondary Prevention 09/2023
1	Combination Drug Therapy (Combination Chemotherapy) 01/2023
1	Intravenous Administration 01/2022